Comparative Pharmacology
Head-to-head clinical analysis: EXPAREL versus LIDOSITE TOPICAL SYSTEM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXPAREL versus LIDOSITE TOPICAL SYSTEM KIT.
EXPAREL vs LIDOSITE TOPICAL SYSTEM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, inhibiting nerve impulse conduction and providing prolonged analgesia.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Local infiltration: up to 266 mg (20 mL) as a single dose; interscalene brachial plexus block: up to 133 mg (10 mL); femoral nerve block: up to 133 mg (10 mL). Maximum dose 266 mg. Administer via slow injection with frequent aspiration.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
None Documented
None Documented
Terminal elimination half-life is 12-48 hours (mean ~24 hours), reflecting prolonged release from the multivesicular liposome depot.
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Renal (approximately 96% as metabolites, <10% unchanged). Biliary/fecal excretion is negligible.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Category C
Category C
Local Anesthetic
Local Anesthetic